Novo Nordisk A/S ($NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug ...

Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...

Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move ...

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

As drugmakers Novo Nordisk and Eli Lilly struggled to keep up with enormous demand for their diabetes and obesity drugs, the ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

Five phase III studies of mazdutide are underway. These trials are looking at how well the drug works in adults with overweight, obesity, and type 2 diabetes. A phase I study of mazdutide ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...